Control BionicsASX:CBL -2.30% PB Ratio is 4.47 as of Jun. 26, 2026, which is 176% above its 10-year median of 1.62. The stock has 7 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Control Bionics ranks worse than 78.17% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Control Bionics's share price is A$0.085. Control Bionics's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.02. Hence, Control Bionics's PB Ratio of today is 4.47.
Warning Sign:
Control Bionics Ltd stock PB Ratio (=4.79) is close to 5-year high of 5.06.
The historical rank and industry rank for Control Bionics's PB Ratio or its related term are showing as below:
ASX:CBL'
s PB Ratio Range Over the Past 10 Years
Min: 0.55 Med: 1.62 Max: 5.06
Current: 4.47
During the past 6 years, Control Bionics's highest PB Ratio was 5.06. The lowest was 0.55. And the median was 1.62.
ASX:CBL's PB Ratio is ranked worse than 78.17% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.045
vs ASX:CBL: 4.47
During the past 12 months, Control Bionics's average Book Value Per Share Growth Rate was -24.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -47.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -40.60% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Control Bionics was -31.10% per year. The lowest was -47.20% per year. And the median was -44.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Control Bionics PB Ratio Related Terms
Control Bionics PB Ratio Historical Data
* Premium members only.
The historical data trend for Control Bionics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Control Bionics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Control Bionics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Control Bionics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Control Bionics (ASX:CBL) has a PB Ratio of 4.47 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Control Bionics and its competitors. This is 176% above median its historical median of 1.62. Over the past decade, Control Bionics' PB Ratio has ranged from 0.55 to 5.06. According to the industry distribution chart, Control Bionics ranks #616 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 78.2%.
Is Control Bionics' PB Ratio too high?
Control Bionics' current PB Ratio of 4.47 is 176% above median its 10-year median of 1.62. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 5.06. The Medical Devices & Instruments industry median PB Ratio is 2.05. Control Bionics' value of 4.47 is 118.6% above this industry median. Based on the distribution chart, Control Bionics ranks #616 out of 788 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Control Bionics' PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #616 out of 788 companies for PB Ratio. This places Control Bionics in the lower half of its industry. The industry median PB Ratio is 2.05. Control Bionics' value of 4.47 is 118.6% above this benchmark. Historically, Control Bionics' own PB Ratio has ranged from 0.55 to 5.06 over the past decade. While the company's 10-year median is 1.62 vs. the industry median of 2.05, Control Bionics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current PB Ratio of 4.47 is 118.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current PB Ratio is 4.47, which is 176% above median its own 10-year median of 1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.09 — trading 183.3% above its estimated fair value. The current PB Ratio is 4.47, which is 176% above median its 10-year median of 1.62 and 118.6% above the Medical Devices & Instruments industry median of 2.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current PB Ratio is 4.47 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 